Abstract
Five years later, what are the wider impacts of the US Supreme Court's Myriad decision on subject-matter eligibility and patent prosecution for nature-based products beyond isolated DNA?
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have